{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009874","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.746738+00:00","generated_at":"2026-06-06T11:07:41.025897+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corbus Pharmaceuticals prices public offering of 4.325M shares at $19, expects ~$88.5M net proceeds","bullets":["Priced 4,325,000 shares of common stock at $19.00 per share; underwriters' option for additional 648,750 shares exercised in full.","Net proceeds expected to be approximately $88.5 million after underwriting discounts and estimated offering expenses.","Offering expected to close on or about February 2, 2024; proceeds to fund clinical pipeline development and working capital.","Jefferies acted as sole book-runner; H.C. Wainwright & Co. and Oppenheimer & Co. as lead managers."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009874","json":"https://secwatch.observer/filing/0000950170-24-009874.json","markdown":"https://secwatch.observer/filing/0000950170-24-009874.md","text":"https://secwatch.observer/filing/0000950170-24-009874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/0000950170-24-009874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/crbp-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:07:41.025897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a0d6b0f0f537f9ffc098371dd5c6997ce01c9c4","claim":"Corbus Pharmaceuticals Holdings, Inc. entered into Underwriting Agreement with Jefferies LLC valued at approximately $88.5 million (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,325,000 shares (the “Base Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), at a price to the public of $19.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/0000950170-24-009874-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"approximately $88.5 million"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}